Optimization of Direct Anti-Viral Agent Treatment Schedule: Focus on HCV Genotype 3

United European Gastroenterology Journal - United States
doi 10.1177/2050640617717158
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Letter: Chronic Hepatitis C Genotype 3 Infection - Still a Hurdle Toward a Direct-Acting Anti-Viral-Induced HCV Cure?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Immunomodulating Effects of the Anti-Viral Agent Silibinin in Liver Transplant Patients With HCV Recurrence

Transplantation Research
TransplantationImmunology
2016English

PMO-167 Presence of Viable HCV RNA in Monocytes at the End of Treatment Predicts Relapse in Genotype 3 HCV Infection

Gut
Gastroenterology
2012English

Viral Genotype and HLA Class II Alleles Influence on Extra-Hepatic Manifestations of Chronic HCV Infection

Reumatismo
Rheumatology
2011English

Anti-Thyroid Antibodies in Patients With HCV Genotype 3a: A Pilot Study

British Microbiology Research Journal
2016English

Treatment of Locally Recurrent Epstein–barr Virus-Associated Nasopharyngeal Carcinoma Using the Anti-Viral Agent Cidofovir

Journal of Medical Virology
VirologyInfectious Diseases
2008English

HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b

BMC Gastroenterology
MedicineGastroenterology
2012English

Short-Term Risk of Hepatocellular Carcinoma After Hepatitis C Virus Eradication Following Direct-Acting Anti-Viral Treatment

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Editorial: Genotype 3 HCV-who Still Needs Ribavirin in a Pan-Genotypic Era?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy